Management of Hyperlipidemia in a 75-Year-Old Woman
In this 75-year-old woman with LDL-C 126 mg/dL, initiate a clinician-patient risk discussion to evaluate her overall cardiovascular risk, frailty, comorbidities, and preferences, then consider moderate- to high-intensity statin therapy if she does not have established ASCVD and the discussion favors treatment. 1
Risk Assessment and Treatment Decision Framework
Step 1: Determine ASCVD Status
- First, establish whether this patient has clinical ASCVD (history of MI, ACS, stroke, TIA, coronary revascularization, or peripheral artery disease) 1
- If she has established ASCVD, she requires moderate- or high-intensity statin therapy regardless of age, after evaluating potential benefits versus adverse effects, drug-drug interactions, and patient frailty 1
Step 2: Primary Prevention Approach (If No ASCVD)
Since this patient is >75 years of age, the standard approach differs from younger adults:
Key considerations for patients >75 years:
- The 2018 ACC/AHA guidelines specifically address this age group, noting that risk calculators are less validated above age 75 and treatment decisions require individualized assessment 1
- Her LDL-C of 126 mg/dL falls in the range where treatment may be beneficial (≥70 mg/dL) 1
- Triglycerides of 152 mg/dL are not a risk-enhancing factor (threshold is ≥175 mg/dL) 1
- HDL-C of 57 mg/dL is protective and not a concern 2
Step 3: Conduct Clinician-Patient Risk Discussion
Before initiating therapy, engage in a mandatory risk discussion that addresses: 1
- Potential ASCVD risk reduction benefits
- Potential adverse effects (statin-associated muscle symptoms, new-onset diabetes risk)
- Drug-drug interactions
- Patient's functional status, frailty, and life expectancy
- Presence of risk-enhancing factors (family history of premature ASCVD, chronic kidney disease, chronic inflammatory disorders, metabolic syndrome) 1
- Patient preferences and values in shared decision-making
Step 4: Treatment Recommendations
If the risk discussion favors statin therapy:
Start with moderate-intensity statin therapy as the preferred approach in patients >75 years 1
- Goal: 30-49% LDL-C reduction 1
- Examples: atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg
High-intensity statin therapy may be reasonable if she is robust, has multiple risk factors, and is already tolerating high-intensity therapy 1
- Goal: ≥50% LDL-C reduction 1
Evidence supporting treatment in this age group:
- Meta-analyses demonstrate that statins reduce major vascular events in patients >75 years, though the absolute benefit may be smaller than in younger patients 3, 4
- Post-hoc analyses from primary prevention trials (JUPITER, HOPE-3) show ASCVD event reduction in patients >65 years 4
- Recent expert consensus (2025) from the National Lipid Association and American Geriatrics Society supports that benefits of statin therapy likely outweigh risks in appropriately selected older adults 5
Step 5: Monitoring and Follow-up
- Reassess lipids 4-12 weeks after initiating therapy to evaluate adherence and response 1
- Monitor for statin-associated side effects, particularly muscle symptoms 1
- Repeat lipid measurements every 3-12 months as needed 1
Important Caveats
When to consider withholding or stopping statin therapy:
- Life-limiting illness with limited life expectancy (<3-5 years) 5
- Significant frailty or functional decline 1
- Patient preference after informed discussion 1
Risk-enhancing factors that would strengthen the case for treatment: 1
- Family history of premature ASCVD
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
- Metabolic syndrome
- History of premature menopause (<40 years)
- Chronic inflammatory disorders (rheumatoid arthritis, psoriasis)
- If measured: hs-CRP ≥2.0 mg/L, coronary artery calcium score ≥100 or ≥75th percentile
The evidence is clear that statins work in women: Meta-analyses demonstrate equal effectiveness in women with CVD for reducing coronary events, mortality, and revascularization 3